SCHEMBL7673733

SCHEMBL7673733

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(OC(=O)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PKM P14618 2/20 0.47
MMP1 P03956 4/20 0.46
ADAMTS4 O75173 2/20 0.46
MMP2 P08253 2/20 0.46
MMP13 P45452 2/20 0.46
MMP14 P50281 2/20 0.46
ADAMTS5 Q9UNA0 2/20 0.46
MEP1B Q16820 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
F2 P00734 3/20 0.45
TMPRSS6 Q8IU80 1/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675632 0.95 SMN1; SMN2 (0.51) MAPTTDP1L3MBTL1PKMMMP1
SCHEMBL7670718 0.88 MMP2 (0.48) MAPTTDP1L3MBTL1ADAMTS4MMP2
SCHEMBL7665205 0.86 F2 (0.58) PKMSMN1; SMN2F2TMPRSS6ALDH1A1
SCHEMBL7669520 0.86 F2 (0.58) PKMSMN1; SMN2F2TMPRSS6ALDH1A1
SCHEMBL28588397 0.85 ALDH1A1 (0.51) PKMMMP1ADAMTS4MMP2MMP13
SCHEMBL7673648 0.84 PKM (0.63) MAPTL3MBTL1PKMMMP1ADAMTS4
SCHEMBL7674174 0.83 MMP1 (0.61) MAPTMMP1ADAMTS4MMP2MMP13
SCHEMBL7676248 0.83 F2 (0.57) SMN1; SMN2F2TMPRSS6ALDH1A1KMT2A
SCHEMBL7673504 0.82 ALDH1A1 (0.54) MAPTPKMMEP1BSMN1; SMN2F2
SCHEMBL7673929 0.82 MMP2 (0.50) PKMMMP1ADAMTS4MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed